Literature DB >> 17093260

Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.

Reina Armamento-Villareal, Nicola Napoli, Vinita Panwar, Deborah Novack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17093260     DOI： 10.1056/NEJMc062268

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  33 in total

Review 1.  Update in women's health for the general internist.

Authors:  Judith M E Walsh; Megan McNamara; Redonda G Miller; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2011-10-13       Impact factor: 5.128

Review 2.  [Bisphosphonates in osteoporosis therapy. Standards and perspectives].

Authors:  S Reinsdorf; B Habermann; K Hochmuth; A A Kurth
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

3.  Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates.

Authors:  Giovam Battista Rini; Delia Sprini; Silvia Migliaccio; Stefania Basili; Rocky Strollo; Francesco Dieli; Nicola Napoli
Journal:  Endocrine       Date:  2014-08-06       Impact factor: 3.633

4.  Removal of pamidronate from bone in rats using systemic and local chelation.

Authors:  R Nicole Howie; Maryka Bhattacharyya; Mohamed E Salama; Mona El Refaey; Carlos Isales; James Borke; Asma Daoudi; Fardous Medani; Mohammed E Elsalanty
Journal:  Arch Oral Biol       Date:  2015-09-07       Impact factor: 2.633

Review 5.  Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.

Authors:  Jordi Bover; Lucía Bailone; Víctor López-Báez; Silvia Benito; Paola Ciceri; Andrea Galassi; Mario Cozzolino
Journal:  J Nephrol       Date:  2017-04-21       Impact factor: 3.902

6.  Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

Review 7.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

8.  CD47 regulates bone mass and tumor metastasis to bone.

Authors:  Ozge Uluçkan; Stephanie N Becker; Hongju Deng; Wei Zou; Julie L Prior; David Piwnica-Worms; William A Frazier; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

9.  Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.

Authors:  T Matsunaga; M Shigetomi; T Hashimoto; H Suzuki; T Gondo; H Tanaka; T Sugiyama; T Taguchi
Journal:  Osteoporos Int       Date:  2007-05-10       Impact factor: 4.507

10.  Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures.

Authors:  Nicola Napoli; Ann V Schwartz; Lisa Palermo; Jenny J Jin; Rosanna Wustrack; Jane A Cauley; Kristine E Ensrud; Michael Kelly; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2013-01-23       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.